Standout Papers

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multice... 2015 2026 2018 2022 452
  1. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial (2015)
    Alice T. Shaw, Leena Gandhi et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 7 from Science/Nature 65 standout
Sub-graph 1 of 19

Citing Papers

Advances in diagnosis and treatment of bladder cancer
2024 Standout
Theranostic Fluorescent Probes
2024 Standout
1 intermediate paper

Works of Jeremy Cetnar being referenced

Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
2021
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
Jeremy Cetnar 879 770 175 362 42 1.4k
Pallavi S. Mishra‐Kalyani 844 537 154 312 49 1.4k
Bo H. Chao 854 822 77 370 46 1.3k
Mireille Mousseau 641 620 236 633 36 1.5k
Rosario García‐Campelo 780 783 90 452 47 1.4k
Ramon Andrade de Mello 731 550 145 464 90 1.3k
Jan Cosaert 1029 630 126 433 43 1.5k
Chan-Young Ock 1004 501 264 301 42 1.4k
Matteo Rosellini 565 639 186 373 47 1.2k
Luisa Carbognin 906 393 124 327 65 1.3k
Angela Listì 685 519 87 412 40 1.2k

All Works

Loading papers...

Rankless by CCL
2026